Leflunomide carries real toxicity risks, serious enough that the FDA assigns it two boxed warnings (the strongest safety label possible): one for liver damage and one for harm to unborn babies. That said, most people tolerate it well with proper monitoring. The drug’s unusual danger comes partly from how long it stays in your body. Its active form has a half-life of about two weeks, meaning it can take up to two years after stopping for the drug to fully clear your system without medical intervention.
Why Leflunomide Lingers in Your Body
Once you take leflunomide, your body converts it into an active compound that suppresses your overactive immune system. This compound sticks around far longer than most medications. With a half-life of roughly two weeks, it takes nearly two months of daily dosing just to reach steady levels in your blood. The flip side is equally important: when you stop taking it, the drug doesn’t leave quickly either.
Without a special washout procedure, traces can remain in your blood for up to two years. This persistence is what makes many of leflunomide’s toxicity concerns more complicated than with other medications. If a serious side effect develops, simply stopping the pill isn’t enough to get the drug out of your system fast. Doctors use a binding agent (cholestyramine, taken three times daily for 11 days) that traps the drug in your gut and pulls it out, shortening the effective half-life from over a week down to about one day. Blood tests taken at least 14 days apart then confirm the drug has dropped to safe levels.
Liver Damage: The Primary Concern
Liver toxicity is the most closely watched risk with leflunomide. Up to 15% of people on the drug develop mild, temporary elevations in liver enzymes, usually in the range of one to three times normal. These elevations are typically asymptomatic, meaning you wouldn’t feel anything wrong. More significant elevations, above three times the upper limit of normal, occur in 1% to 4% of patients and require dose changes or stopping the drug.
At the severe end, fatal liver failure has occurred in some patients. People with pre-existing liver disease or already elevated liver enzymes should not take leflunomide at all. The FDA label requires liver enzyme monitoring at least monthly for the first six months, then every six to eight weeks after that. The American College of Rheumatology recommends an even more structured schedule: every two to four weeks for the first three months, every eight to twelve weeks for months three through six, then every twelve weeks going forward.
Combining leflunomide with methotrexate (another common rheumatoid arthritis drug) raises the stakes. Mild liver enzyme bumps have been reported in up to 45% of patients on the combination, and marked elevations requiring treatment discontinuation occur in under 10%. The combination has been linked to documented cases of liver failure and death, though these outcomes remain rare.
Blood Cell Suppression
Because leflunomide works by suppressing the immune system, it can also suppress the bone marrow’s ability to produce blood cells. Pancytopenia, a dangerous drop in red cells, white cells, and platelets simultaneously, occurred in 0.01% to 0.1% of patients in clinical trials. That’s rare, but because the consequences can be life-threatening (severe infections, uncontrolled bleeding), regular complete blood counts are part of the standard monitoring schedule, following the same timeline as liver enzyme tests.
The risk of blood cell suppression increases when leflunomide is combined with other immune-suppressing drugs. Bone marrow toxicity from leflunomide is generally reversible once the drug is eliminated, but the slow clearance time means a washout procedure is often necessary to speed recovery.
Pregnancy and Fertility Risks
Leflunomide is one of the more dangerous prescription drugs for pregnancy. In animal studies, it caused severe birth defects including missing or abnormally small eyes and fluid buildup in the brain, even at exposure levels one-tenth of what humans typically experience. In rabbits, it caused bone malformations at exposure levels equivalent to normal human doses. At very low doses in rats (about 1/100th of typical human exposure), over 90% of offspring did not survive after birth.
Because of these findings, pregnancy must be ruled out before starting treatment. Women of childbearing age must use reliable contraception the entire time they take leflunomide. If you want to become pregnant after stopping the drug, you can’t simply wait it out. The washout procedure is required, followed by two blood tests at least 14 days apart confirming the drug has dropped below detectable levels. Without the washout, the drug could remain in your body at potentially harmful levels for months or even years.
Skin Reactions
Rare but severe skin reactions have been reported with leflunomide, including toxic epidermal necrolysis, a condition where the skin essentially blisters and peels off in sheets. Only a handful of cases appear in the medical literature, making this an uncommon complication, but it requires immediate discontinuation and an emergency washout to clear the drug. Any new, widespread, or blistering rash while taking leflunomide warrants urgent medical attention precisely because the drug clears so slowly on its own.
What Monitoring Looks Like in Practice
If you’re prescribed leflunomide, expect frequent blood draws, especially in the first six months. Both liver enzymes and complete blood counts are checked at baseline before you start, then every two to four weeks for the first three months. After that initial period, testing spaces out to every eight to twelve weeks, and eventually settles into a routine of every twelve weeks for as long as you take the drug.
This monitoring schedule is more intensive than what many people expect from a daily pill, and it’s the main reason leflunomide’s serious toxicities are usually caught early. Most liver enzyme elevations are mild and reversible. Severe outcomes like liver failure or dangerous drops in blood counts, while documented, are uncommon when monitoring guidelines are followed. The drug’s overall safety profile is considered acceptable for the conditions it treats, primarily rheumatoid arthritis, but that profile depends entirely on consistent lab work and prompt action when numbers shift.